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1715-41 Thrombolytic Therapy During the "Golden Rrst Hour"
in GUSTO
The cost of hospitalization was significantly greater in pts with recurrent
ischemia ($21,069vs. $17,492, p = 0.02) or reinfarction ($22.772 vs. $17,721,
p = 0.06) compared with patients without these complications.
Thus; These findings suggest that a strategy of prophylactic IASP therapy
after patency has been established during acute myocardial infarction while
improving clinical outcomes does not increase hospitalization cost.
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1715-3 [ Cost Implications of Aortic Counterpulsation in Acute
Myocardial Infarction: Results from a Randomized
Clinical Trial
J. David Talley. E. Magnus Ohman. Barry S. George. Morton J. Kern. Christopher
J. White. Conor Lundergan. Joseph R. Hartmann. Paul A. Gurbel. Harry R. Phillips.
Lisa G. Berdan. Lai Choi Lam. Robert M. Califf. Daniel B. Mark. University of
Arkansas. Uttle Rock. AR; Duke University, Durham. NC
To evaluate the cost implications of prophylactic aortic counterpulsation
(IASP) to sustain coronary artery patency during acute myocardial infarction.
we evaluated 102 (55%) from the 182 patients enrolled in the randomized
IABP study. After coronary artery patency was established during acute car-
diac catheterization. pts were randomized to IABP (N = 52) for 48 hours ver-
sus standard therapy. Control (C) = 50. During the hospitalization. pts with
IASP had less recurrent ischemia (4% vs. 21 %). less reinfarction (3% vs. 8%1.
less reocclusion (8% vs. 21 %). and less need for emergency PTCA (2% vs.
11 %). The duration of hospitalization (IASP = 104vs. C = 9.7 daysl and CCU
stay (IABP = 4.7 vs. C = 3.9 days) were similar. The outcomes were similar
in the sUbstudy compared with the overall clinical trial. Median costs were:
9% lower among the first hour pts (and not different between t-PA and SK
groups) than among those treated later, comparable to the overall 14% mor-
tality reduction by t-PA compared with SK in the main trial. Thus, despite
the apparent existence of a "golden first hour" during early reperfusion tri-
als, outcome following thrombolysis during the first hour in GUSTO was only
modestly better than among patients treated later.
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1715-51 Reteplase vs Alteplase Patency Investigation During
Myocardial Infarction Trial (RAPID 2)
W. Douglas Weaver. Christoph Bode, Curtis Burnett, John Kalbfleisch,
Gerald Lorch, Semi Sen, Robert Chernoff, Richard Smalling. RAPID 2 Trial
Investigators. University of Washington, Seattle. WA
It has been previously shown that double-bolus reteplase (r-PA) resulted in
superior TIMI 3 flow rates at 60 and 90 minutes and follow-up compared
to "standard" dose (100 mg/3 hours) alteplase (t-PA). To test whether this
regimen was also superior to "accelerated" (100 mg/90 minutes) dose t-PA
we studied 320 patients with acute myocardial infarction (MI). Patients were
randomized to receive either 10 + 10 mu (30 minutes apart) bolus doses of r-
PA or a 90-minute "accelerated" dose of t-PA. All patients received aspirin and
IV heparin. Patency and TIMI3 flow rates were determined at 30,60, and 90
minutes and prior to discharge. The trial was completed 1 September 1994.
A preliminary analysis of the baseline characteristics in the first 164 patients
showed the average age was 58.4 years, 79% were male, 52% were current
smokers. 9% had a prior history of MI. 43% had hypertension. and 25% had
prior angina. The median time to treatment was 2.2 hours (25-75%tiles, 1.6-
3.8 hours). The infarct related artery was the anterior descending in 36%. the
right coronary in 52%. and the circumflex artery in 11 % of patients.
In the combined data from both treatment groups, there were 14 deaths
(8.6%). 4 strokes (2.4%). and 15.9% had "rescue" PTCA at 90 minutes be-
cause of continued coronary occlusion.
A complete comparative analysis of the angiographic and clinical findings
in the r-PA and "accelerated" t-PA treatment groups will be presented.
Total $
17.903
17.913
Non-ICU $
1.804
1.851
CCU/ICU $
3.239
2.781
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5.910
5.679
IABP
Control
<1 hr 1-6 hr <1 hr 1-6 hr
Age (yrsl 60.1 60.9 Killip 3 or 4 (%) 21 2.0
Male(%) 78.8 74.8 Systolic BP (mm) 127 129
Prior Angina (%) 46.4 36.5 Pulse (bpm) 75 75
Prior MI (%) 20.7 16.1 Anterior MI (%) 43 39
A. Michael Lincoff. Robert M. Califf, Wolfgang Rutsch. Amanda Stebbins. Eric
J. Topol. GUSTO Investigators. Cleveland Clinic Foundation. Cleveland. OH
Data derived from thrombolytic trials performed during the placebo-
controlled era have suggested that initiation of reperfusion therapy during
the "golden first hour" after onset of infarction may dramatically reduce mor-
tality and improve myocardial salvage. Pts presenting within 1 hr in these
early studies may also have differed from those presenting later by hav-
ing larger infarctions or more hemodynamic compromise; early therapy may
thus compensate for the high-risk profile of these patients. To determine in
a large contemporary cohort the extent to which early-treated pts differ with
regard to baseline characteristics and clinical outcome from pts presenting
later, 1269 pts (3.2% of total) randomized to 4 different thrombolytic regi-
mens within 1 hr of symptom onset (mean 0.8 ± 0.2 hr) were compared
with 38,562 pts treated between 1 and 6 hrs (mean 3.2 ± 1.6 hr) in GUSTO.
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3:15
!715-6!lnternational Joint Efficacy Comparison of
Thrombolytics (INJECT): Reteplase vs Streptokinase
in Acute Myocardial Infarction
John Hampton, Wolfgang Meyer-Sabellek. Rolf Schroder. Robert Wilcox. INJECT
Trial Study Group. University of Nottingham, UK; Universitiitsklinikum Benjamin
Franklin, Berlin, Germany
Reteplase (r-PA) is a non-glycosylated recombinant plasminogen activator
containing the kringle-2 and protease domains but lacking the finger, epi-
dermal growth factor and kringle-1 domains. It has a longer half-life than
native t-PA and the 20 MU dose administered as two 10 MU boluses sepa-
rated by 30 minutes has been shown to achieve a 90 minute patency rate
of 85%. The objective of the INJECT trial was to compare the efficacy and
safety of this r-PA regimen with standard regimen Streptokinase (1.5 M U over
60 minutes) in patients with acute myocardial infarction receiving treatment
within 12 hours of symptom onset. A double-blind. double-dummy design
was employed and standard inclusion/exclusion criteria for thrombolysis ap-
plied. The primary endpoint was 35 day survival. Target recruitment was 6000
patients, this number providing good power to determine the clinical benefit
of r-PA. Total recruitment was achieved over one year to September 1994.
211 Coronary Care Units in 9 countries participated. This paper will present
for the first time the results of INJECT and thus provide a detailed character-
isation of the efficacy and safety (including mortality) of Reteplase, a second
generation direct plasminogen activator.
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Mortality (30-Day) Death + Stroke
Pts receiving thrombolysis early «1 hr) in the course of MI did not differ
substantially with regard to severity of MI or any baseline clinical parameter
from those presenting 1-6 hrs after symptom onset, except for a trend to-
ward more frequent prior angina in the <1 hr group. Mortality (30-dayl was
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\716-1 I Long-term Prognostic Significance of
Exercise-Induced Silent Myocardial Ischemia in
Apparently Healthy Volunteers
Jerome L. Fleg. Alan B. Zonderman. Lewis C. Becker, Steven P. Schulman,
Gary Gerstenblith, Edward G. Lakatta. Gerontology Research Center. NlA, NIH. and
Johns Hopkins Bayview Medical Center. Baltimore. MD
Silent myocardial ischemia (SI) defined by concordant ST segment depres-
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sian on ECG and a planar thallium (TL) perfusion defect during maximal tread-
mill testing was a potent independent predictor of future coronary events
(CE) over a mean follow-up of 4.7 years in 407 asymptomatic volunteers
aged 40-96 years (mean = 60) from the Baltimore Longitudinal Study of
Aging (Circulation 1990;81 :428). To determine the longer term prognostic
significance of SI in this population. we examined the incidence and predic-
tors of CE over a mean follow-up of 9.2 years. A total of 61 CE developed (32
cases of new angina pectoris. 17 non-fatal myocardial infarctions. 12 cardiac
deaths). Events occurred in 15% of subjects with both negative ECG and TL
responses. 30% of those with either a positive ECG or TL result. and 48%
of those in whom both tests were positive (p < 0.001). By proportional haz-
ards analysis. older age (relative risk [RR] = 2.3 per 15 year incrementl. male
gender (RR = 2.2), hypertension (RR = 2.5). shorter exercise duration (RR
= 0.91 per minute). and a concordant positive ECG and TL response (RR =
2.5) were significant independent predictors of CEo Hard CEo i.e. myocardial
infarction orcardiac death, were predicted by older age (RR = 3,1), male gen-
der (RR = 2.8), current smoking (RR = 3,0). plasma cholesterol (RR = 1.01
per mg/dl). fasting plasma glucose (RR = 1,01 per mg/dll and a concordant
positive ECG and TL (RR = 3.4). Thus, at a mean follow-up of over 9 years,
exercise-induced SI remains a potent predictor of future CE in apparently
healthy volunteers. independent of conventional risk factors,
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1716-21 Myocardial Ischemia Induced by Mental Stress
Predicts a Poorer Prognosis in Patients with
Coronary Artery Disease
Wei Jiang, James A. Blumenthal, Steven E, McNulty, Michael W Hanson, R.
Edward Coleman, David J, Frid, Robert A. Waugh. James J, Morris, Christopher
M, O'Connor. Duke University Medical Center, Durham, NC
Although it is clear that mental distress elicits myocardial ischemia, the re-
lationship of mental stress-induced myocardial ischemia (MSI) to prognosis
in patients with CAD is unknown. 130 CAD patients with stable angina un-
derwent a series of mental stress and exercise tests using radionuclide ven-
triculography and standard 12-lead ECG. then were followed for one year,
Myocardial ischemia was defined as a new wall-motion abnormality, ejec-
tion fraction (EF) decrease >5%. or ST-segment depression 2:0.1 mV from
baseline, Cardiac events (CE) were defined as CABG, PTCA, unstable angina
admission requiring angiography (UA), nonfatal myocardial infarction (NMI),
and cardiac death.
Of the 130 patients. 50% had both MSI and exercise-induced ischemia
(ESI). 18% experienced MSI alone. and 18% had ESI alone. Of the 117 pa-
tients achieving one-year follow-up. 20 suffered various CE: 19 had UA, 9
had PTCA. 4 had CABG. 2 had NMI, and 1 died. Logistic regression analyses
were performed to examine the possible relationships among age, baseline
systolic blood pressure (SBP). baseline EF. MSI. ESI and CEo Results showed
that baseline SBP and MSI, but not ESI, were univariable predictors of CE
(see Table). Multivariable logistic models were then used, with age. baseline
SBP. and baseline EF as covariables. to determine if the addition of either
MSI or ESI provided prognostic information in predicting CEo MSI was inde-
pendently predictive of CE after adjustment for the covariables,
Univariable x2 p Value
Age 0.49 0.48
Baseline SBP 5.32 0,02
Baseline EF 0.001 097
MSI 4.77 0,03
ESI 0.48 0.49
In conclusion, MSI may have greater prognostic potential than ESI for a
specific population of CAD patients.
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1716-31 Prognostic Significance of Transient Ischemic
Episodes; Response to Treatment Shows ImprOVed
Prognosis. Results of the TIBBS-follow-up
Th. v. Arnim. TIBBS (Total Ischemic Burden Bisoprolol Study) investigators. Red
Cross Hospital, Munich. Germany
TIBBS is a multi-center trial in which patients with stable angina pectoris and
a positive exercise ECG were selected for randomized medical treatment
when they showed transient ischemic episodes (TIE) on 48-h-ambulatory
ECG monitoring (AECG). The follow-up study at 1 year investigates the im-
plications for the prognosis of the patients.
Of 621 patients screened on the basis of history of stable angina pectoris
and positive exercise ECG. 565 had technically sufficient 48-h-AECG. and
193 showed 0 or 1 TIE (1 mm, 1 min. 1 min. apart) 152 showed 2-6 TIE. 153
showed >6 TIE. Follow-up at one year was >90% complete, Physicians in
charge of the patients were unaware of the results of AECG,
Patients with 0-1 TIE had less cardiac events (death. AMI. CABG, PTCA,
hospitalisation for unstable A.p.) at one year (11.9%) compared to patients
with 2-6 TIE (+26.3%) or patients with >6 TIE (30.5%) (p < 0.001),
Of 268 randomized patients. those 90 patients who had shown response
to medical treatment with 100% reduction of TIE during the 8-week active
phase of TIBBS (treatment with Bisoprolol 10 mg/20 mg o,d. vs. Nifedipin
slow release 2 x 20/2 x 40 mg b,Ld.) had better prognosis: 17.8% events
compared to 30.6% events in patients with less or no reduction of TIE (p <
0,025). Patients who responded with 50% reduction of TIE showed only a
trend towards reduced risk of events: 23.3% vs 30.9% (p < 0,117).
Conclusion: AECG in patients with stable angina pectoris and positive ex-
ercise ECG selects patients with increased risk of cardiac events, Patients
who do not respond to medical treatment with reduction of TIE are at fur-
ther increased risk.
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Placebo Treatment Reduces Both the Number of
Ischemic Episodes and Duration of Ambulatory
Silent Myocardial ischemia in Patients with Stable
Angina Pectoris
Udho Thadani. University of Oklahoma HSC, Oklahoma City, OK
Ambulatory silent myocardial ischemia occurs frequently in patients with
stable exertional angina pectoris, It is widely accepted that a medication
has antiischemic effects if it reduces either the number or the duration of
silent myocardial ischemic episodes in comparison to pretreatment values.
Effect of monotherapy with placebo on silent myocardial ischemia in 33 pa-
tients who took part in a parallel group investigational drug study and were
assigned to the placebo arm of the study form the basis of this investiga-
tion. After discontinuation of all antianginal medications patients received
two weeks of single blind placebo treatment followed by four weeks of dou-
ble blind placebo treatment. Ambulatory holter monitoring was performed
for 48 hours after two weeks of single blind placebo treatment and again
after 4 weeks of double blind placebo treatment. The median value of silent
myocardial ischemia attack rate during single blind placebo treatment was
7.2 episodes per 48 hours and decreased during double blind placebo treat-
ment to a median rate of 3.1 episodes per 48 hours (P < 0.004; 95% CI.
-5.41. -1.0), Similarly the duration of silent myocardial ischemic episodes
decreased by a median of 16,1 minutes per 48 hours (P < 0,001; 95% CI.
-35.7. -6.2 minutes) during double blind placebo treatment from a median
value of 24.8 minutes per 48 hours during single blind placebo treatment.
Conclusion: placebo monotherapy had a marked influence on ambulatory
silent myocardial ischemia and reduced both the duration and number of
silent myocardial ischemic episodes in patients with stable angina pectoris.
These findings have important implications for interpretation of studies in
which the effects of active treatment on silent myocardial ischemia are com-
pared to baseline pretreatment values.
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1716-51 Treatment of Silent Ischemia in Unstable Angina: A
Randomized Comparison of Sustained-release
Verapamil Versus Metoprolol
Narendra Singh, Dmitry Mironov, Shaun Goodman, Chris 0, Morgan,
Anatoly Langer, St. Michael's Hospital, Toronto. Ontario. Canada
Silent ischemia is a frequent finding in pts with unstable angina IUA) which
portends a poor prognosis. We compared the efficacy of sustained-release
verapamil and metoprolol (M) in the treatment of silent ischemia and stud-
ied whether detection of silent ischemia was related to unfavourable out-
comes irrespective of treatments. Consecutive pts with UA were random-
ized to therapy with verapamil or metoprolol and all received nitrates, hep-
arin and aspirin by protocol. ST shift (2: 1 mm. 60-80 msec after J point and
separated by 2: 1 min from other episodes) was detected on 72 hr Holter
monitoring Ileads AVF, V2. V5)·
There were 37 pts in the verapamil (218 ± 89 mg/day) and 40 pts in the
metoprolol (88 ± 24 mg/day) group. The two groups were similar in baseline
characteristics. Recurrent angina episodes were more frequent in the ver-
apamil group 129 vs 12. p = 0.05). Overall 26 (34%) pts had 100 episodes
of ST shift, 75% ST.J,. 95% silent. Comparing the verapamil vs metoprolol
group. there was no difference in the frequency (51 vs 49 episodes, p = 0.9)
and duration (23 ± 48 min vs 18 ± 50 min, p = 0.6) of ST shift episodes. 20
in-hospital unfavourable outcomes 15-MI, 15-urgent revascularization) were
distributed equally between verapamil and metoprolol pts. However. pts with
unfavourable outcomes irrespective of treatment more often had ST shift
(50% vs 28%, P = 0.07), and with longer duration 140 ± 69 vs 13 ± 38 min,
p = 0.03), Pts with ST shift 2:60 min had a 60% probability of unfavourable
outcome compared with 33% for ST shift between 1-59 min and 20% for
pts without ST shift Ip = 0.04).
